AXS25 DigitalGuide V2 04.18 pages - Flipbook - Page 24
GSK at
a glance
Who we are
What we do
We are a focused
biopharma company
with a purpose to unite
science, technology and
talent to get ahead of
disease together.
We aim to positively impact the
health of more than 2.5 billion
individuals by the end of the
decade with ambitious plans for
growth and continuing to make
GSK a company where everyone
can thrive.
We prevent and treat
disease with specialty
medicines, vaccines and
general medicines.
We focus on the science of the
immune system and advanced
technologies, investing in 4 core
therapeutic areas (respiratory,
immunology and inflammation;
oncology; HIV; and infectious
diseases) to impact health at scale.
In 2024:
£31.4bn
71
medicines and
vaccine sales
medicines
and vaccines
in development
£6.4bn
13
R&D investment
We operate responsibly for all our
stakeholders by prioritising Innovation,
Performance and Trust.
positive
phase III readouts
Our portfolio:
Specialty Medicines
Vaccines
General Medicines
Our specialty medicines prevent and treat
diseases, from HIV, cancer and asthma to
immune-inflammation diseases like lupus.
Our broad vaccines portfolio targets
infectious diseases at every stage of life.
From antibiotics to inhaled medicines
for asthma and COPD, we have a broad
portfolio of general medicine products,
many of them leaders in their class, making
life better for millions of people worldwide.
